- 13 hours ago
- 11 min read
Key Takeaways
Multiple approved CAR-T options: China has several NMPA-approved CAR-T products for relapsed/refractory large B-cell lymphoma — including relmacabtagene autoleucel (relma-cel) and locally manufactured axicabtagene ciloleucel (Yescarta) — giving patients more approved pathways than in most Western countries.
Dramatic cost difference: A complete CAR-T treatment package for lymphoma in China commonly runs $120,000–$180,000 USD all-in, versus $500,000–$800,000+ for the same category of treatment in the US once hospital fees and monitoring are included.
Concentrated expertise, not scattered options: Fewer than a dozen hospitals in China are equipped to deliver CAR-T therapy to international patients, because it requires specialized apheresis equipment, GMP-grade cell manufacturing, and ICU-level capability for managing cytokine release syndrome (CRS) — so hospital choice matters enormously.
National academic centers lead: Institutions like Peking Union Medical College Hospital (PUMCH), Sun Yat-sen University Cancer Center (SYSUCC), and Peking University Cancer Hospital consistently rank at the top of China's specialty reputation surveys for hematologic malignancies, including lymphoma.
Why China Has Become a Serious Option for Lymphoma Treatment
Lymphoma — particularly diffuse large B-cell lymphoma (DLBCL), the most common aggressive form — has become one of the clearest success stories for CAR-T cell therapy globally. The problem for most patients outside China is access: US list prices for approved CAR-T products like Yescarta and Kymriah run $373,000–$475,000 before hospital fees, and total treatment costs (including pre-conditioning chemotherapy, hospitalization, and CRS management) frequently reach $500,000–$800,000.
China took a different regulatory and industrial path. Chinese biotech companies developed their own CAR-T constructs under the NMPA's conditional approval pathway — comparable in structure to the FDA's Accelerated Approval program — bringing multiple lymphoma-indicated CAR-T products to market since 2021 at a fraction of US pricing.
Combine that with China's enormous hematology case volume (some centers manage thousands of lymphoma cases annually) and a fast-expanding network of international patient departments, and it's easy to see why more patients are researching treatment there — provided they choose the right hospital.
How These Hospitals Were Chosen
Hospital reputation in China is typically benchmarked using the Fudan University Hospital Management Institute's annual specialty reputation rankings — an independent survey drawing on thousands of Chinese Medical Association and Chinese Medical Doctor Association specialists — combined with National Health Commission designations and clinical trial activity.
The hospitals below were selected based on:
Hematology/lymphoma-specific specialty reputation ranking
NMPA authorization to administer commercial CAR-T therapy
Documented international patient department and multilingual support
Published case volume and clinical trial participation
A note on transparency: some figures below — particularly exact case volumes and survival outcomes — rely on institutional reporting rather than independently audited registries. Treat hospital rankings as a strong starting point for research, not a guarantee of outcome, and always confirm current details directly.
The Top 5 Lymphoma Hospitals in China
1. Lu Daopei Hospital, Beijing
Lu Daopei Hospital is one of China's leading specialized centers for hematologic malignancies and cellular therapy. It is particularly well known for advanced lymphoma and leukemia treatment, CAR-T therapy, and stem cell transplantation. The hospital has extensive experience treating complex cases and international patients seeking advanced blood cancer therapies.
Best for: Patients with relapsed or refractory lymphoma, CAR-T therapy, stem cell transplantation, or complex hematologic malignancies.
2. Peking Union Medical College Hospital (PUMCH), Beijing
PUMCH is one of China's most prestigious comprehensive academic hospitals, with a highly experienced hematology department. Its multidisciplinary approach makes it particularly suitable for patients with rare, complex, or atypical lymphoma presentations and those with other significant medical conditions.
Best for: Complex or rare lymphoma cases requiring multidisciplinary specialist care.
3. Peking University Cancer Hospital, Beijing
Peking University Cancer Hospital is a major cancer center with specialized expertise in lymphoma and cancer immunotherapy. Its research programs include novel immunotherapy approaches and clinical studies for aggressive lymphoma subtypes.
Best for: Patients seeking advanced lymphoma treatment, immunotherapy, and access to clinical research.
4. Sun Yat-sen University Cancer Center (SYSUCC), Guangzhou
SYSUCC is one of China's leading academic cancer centers, with extensive experience in hematologic malignancies and a strong research infrastructure. Its high patient volume and international patient services make it an attractive option for overseas patients.
Best for: Patients seeking comprehensive cancer care, clinical trial opportunities, and treatment at a high-volume academic center.
5. Ruijin Hospital, Shanghai
Affiliated with Shanghai Jiao Tong University School of Medicine, Ruijin Hospital has a long-standing reputation in hematology and blood cancer research. Its hematology department has extensive experience in lymphoma and other hematologic malignancies, combining clinical expertise with academic research.
Best for: Patients looking for a major academic hematology center with strong research and clinical expertise.
CAR-T Therapy for Lymphoma: What's Actually Approved
Unlike CAR-T for solid tumors — which remains largely experimental worldwide — CAR-T for B-cell lymphomas is a mature, commercially approved therapy in China, with several products on the market:
Product | Manufacturer | Approved Indication |
Relmacabtagene autoleucel (relma-cel / Carteyva) | JW Therapeutics | Relapsed/refractory large B-cell lymphoma |
Axicabtagene ciloleucel (Yescarta) | Fosun Kite (China license) | Large B-cell lymphoma, follicular lymphoma |
Additional NMPA-approved CD19 CAR-T products | Various Chinese biotech firms | DLBCL, mantle cell lymphoma, follicular lymphoma (indication-dependent) |
How well does it work?
In a published Phase 1 trial of relma-cel, the best overall response rate reached 85%, with a complete response rate of 75% among evaluable patients; two-year progression-free and overall survival rates were reported at 60% and 70% respectively. The most common side effects were blood-count related (neutropenia, leukopenia), with cytokine release syndrome occurring but generally manageable — two patients experienced grade 2 CRS and one grade 3 CRS, resolved with standard treatment.
These are real, published clinical outcomes for a specific patient population — not a guarantee for every case. Eligibility depends heavily on lymphoma subtype, prior treatment history, and overall fitness for the procedure.
Currently approved lymphoma indications generally include:
Diffuse Large B-Cell Lymphoma (DLBCL) — the most common indication, typically for patients relapsed after or refractory to two or more lines of systemic therapy
Follicular Lymphoma (FL) — relapsed/refractory after two or more prior lines
Mantle Cell Lymphoma (MCL) — relapsed/refractory disease
Cost Breakdown: Lymphoma Treatment in China
Costs vary by hospital, product, and case complexity — but the gap versus Western pricing is consistent and substantial.
Cost Component | China (Estimated) | United States (Typical) |
Pre-treatment evaluation & eligibility workup | $1,100 – $2,100 | Often billed separately, similar or higher |
Complete CAR-T package (drug, 14–21 day hospitalization, CRS/ICANS monitoring, imaging, follow-up) | $120,000 – $180,000 | $500,000 – $800,000+ |
International patient coordination surcharge | Approximately 20–30% additional | N/A |
Standard chemoimmunotherapy (non-CAR-T lymphoma treatment) | Significantly below Western pricing, case-dependent | Varies widely by regimen and insurance |
Reality check:
Publicly reported total treatment ranges across current market sources vary fairly widely — from roughly $120,000 up to $178,000 for a complete package depending on hospital and what's bundled in. Always request a written, itemized quote after a remote case review rather than relying on any single published figure, since drug cost, hospitalization length, and complication management can all shift the final bill.
Am I Eligible? Key Criteria to Check First
Before booking anything, confirm these basics with the treating hospital:
Confirmed lymphoma subtype and staging, via pathology review (often requiring your existing biopsy slides or a fresh biopsy)
Treatment history — most CAR-T indications require failure of at least two prior lines of systemic therapy
Organ function and overall fitness to tolerate leukapheresis, lymphodepleting chemotherapy, and the CAR-T infusion itself
CD19 or relevant target-antigen status confirmed by biomarker testing, depending on the specific product
Most reputable hospitals offer a remote multidisciplinary case review before you travel — this is the right first step, not a flight booking.
How to Get a Visa for Lymphoma Treatment in China
International lymphoma patients typically use one of two visa categories, depending on expected treatment length:
S2 Visa (Most Common)
For medical stays under 180 days — sufficient for most CAR-T timelines, including workup, leukapheresis, manufacturing wait, infusion, and initial monitoring.
Typical requirements:
Official invitation/diagnosis letter from a recognized Chinese hospital
Diagnostic records and treatment history
Proof of funds covering estimated treatment costs
Travel/medical insurance covering emergency care
S1 Visa
For treatment expected to exceed 180 days, with the option to convert to a residence permit after arrival — relevant for patients needing extended monitoring or a second treatment cycle.
Practical tip: Begin the visa process as soon as you receive your hospital's invitation letter, and build in at least 4–6 weeks of buffer before your planned treatment date, since requirements vary by nationality.
Choosing the Right Hospital for Your Lymphoma Subtype
There's no single "best" hospital for every lymphoma patient — the right fit depends on your specific diagnosis:
Aggressive B-cell lymphomas (DLBCL) needing CAR-T: Prioritize hospitals with established CAR-T infrastructure and ICU-level CRS management — GoBroad Healthcare Group, Peking University Cancer Hospital, and SYSUCC all fit this profile.
Rare or atypical lymphoma subtypes: PUMCH's breadth of sub-specialists is particularly valuable for unusual presentations.
Pediatric lymphoma: Beijing Jingdu Children's Hospital's dedicated pediatric hematology infrastructure is purpose-built for this population.
Patients wanting deep research pedigree: Ruijin Hospital's decades of hematology research make it a strong option for complex or research-adjacent cases.
Before choosing, verify: current NMPA authorization to treat international patients, published age/subtype-specific outcome data (not just a single headline statistic), and a transparent written cost estimate.
Approved CAR-T vs. Clinical Trial CAR-T
One of the most important distinctions patients should understand is the difference between an approved CAR-T treatment and an investigational CAR-T therapy.
An approved product has passed the relevant regulatory review for specific indications. A clinical-trial CAR-T may involve:
A new target
A new CAR design
A dual-target construct
An allogeneic or donor-derived product
A new manufacturing method
A new cancer indication
Clinical trials can be important for patients who have exhausted standard options, but participation requires meeting specific eligibility criteria. A hospital conducting a large number of CAR-T trials does not mean that every patient will qualify for one.
Why CAR-T Hospital Experience Matters
CAR-T treatment is not simply an infusion.
The treatment pathway can include:
Medical-record and eligibility assessment
Target-antigen testing
T-cell collection through leukapheresis
CAR-T cell manufacturing
Bridging therapy when necessary
Lymphodepleting chemotherapy
CAR-T infusion
Monitoring for cytokine release syndrome
Monitoring for ICANS and other neurological complications
Infection prevention and treatment
Disease-response assessment
Long-term follow-up
The patient may therefore spend several weeks or longer in close contact with the treating center. This is why hospital infrastructure matters.
Should You Travel to Another Country for CAR-T Before Getting a Second Opinion?
Usually, it is better to have the case reviewed before traveling. CAR-T treatment involves significant preparation, and international travel adds additional complexity.
A remote specialist review can help determine:
Whether CAR-T may be appropriate
Which target may be relevant
Whether an approved product is available
Whether a clinical trial may be appropriate
Whether another treatment should be given first
Whether transplantation should be considered
Which hospital is most relevant to the case
Only after these questions are addressed does it make sense to seriously consider international travel.
How ChinaCureLink Can Help Compare CAR-T Options
For an international patient, finding a CAR-T hospital is not simply a matter of choosing the hospital with the biggest name. The patient needs to identify the center whose specific expertise matches the disease and treatment history.
ChinaCureLink provides oncology second opinions and hospital matching in China, including coordination of medical records, specialist consultations, hospital selection, and international treatment logistics.
For patients specifically researching CAR-T, ChinaCureLink's CAR-T treatment guide for international patients explains CAR-T options, eligibility considerations, and the treatment landscape in China.
Its step-by-step guide to getting CAR-T in China explains the practical process from medical-record submission through specialist evaluation and treatment coordination.
Get a CAR-T Second Opinion Before Choosing a Hospital
If you are comparing CAR-T hospitals around the world, you do not necessarily need to choose one immediately.
A more useful first step is to have your case reviewed by specialists who can determine which treatment centers are actually relevant to your disease.
Depending on the diagnosis and treatment history, the review can help determine which specialist center should be considered.
The specialist can discuss:
Whether CAR-T is appropriate
Which CAR-T target may be relevant
Whether an approved product or clinical trial may be appropriate
Whether additional testing is required
Whether bridging therapy may be needed
Whether transplantation should be considered
What alternative treatment options remain
For suitable cases, ChinaCureLink can then coordinate an online consultation with the specialist to discuss the technical treatment details directly. The purpose is to help the patient understand which treatment option and which specialist center may be most appropriate before making an international treatment decision.
What Patients Say About ChinaCureLink & Medebound HEALTH
China CureLink operates under Medebound HEALTH — an internationally recognized healthcare navigation company incorporated in New York, with operations across North America and Asia-Pacific.
Rated 4.6 ⭐⭐⭐⭐⭐ at Trustpilot
Medebound HEALTH's online testimonials. Learn More
★★★★☆ Sarah Zhang · Canada· Jul 2024 · Verified “The interpreter during the video call was fantastic — super professional and answered all our questions clearly and quickly. The professor was also very patient and gave us detailed and honest guidance on our treatment options.” |
★★★★★ Andrew Goh · Singapore · Aug 2024 · Verified “My first contact with Medebound was over a year ago. Jason has always been responsive, even when I wasn't ready to proceed. When I finally did, the consultation was seamlessly arranged and the specialist was outstanding.” |
★★★★★ Daniel Wong · Singapore · Aug 2024 · Verified “I have dry eye and nothing seemed to be working, even with different medications. I heard about a medication from the U.S. that’s supposed to be really effective, but I didn’t want to try it without talking to a doctor first. MEDEBOUND connected me with a top ophthalmologist in the U.S. and it was so reassuring to get their expert advice.” |
FAQ: Frequently Asked Questions
1. How much does lymphoma treatment with CAR-T cost in China?
A complete CAR-T treatment package for relapsed/refractory large B-cell lymphoma — including the drug, hospitalization, and monitoring — typically runs $120,000–$180,000 USD in China, compared to $500,000–$800,000+ for equivalent treatment in the United States. Costs vary by hospital and case complexity, so always request a written, itemized quote after a remote case review rather than relying on a single published figure.
2. How can an international patient access lymphoma treatment in China?
Start with a remote case review at a hospital with an established international patient department — such as PUMCH, SYSUCC, Peking University Cancer Hospital, or GoBroad Healthcare Group. You'll typically need pathology confirmation of your lymphoma subtype, documented treatment history (most CAR-T indications require failure of at least two prior therapy lines), and biomarker testing. Once accepted, the hospital issues an official invitation letter used for your visa application, and treatment — leukapheresis, manufacturing, infusion, and monitoring — generally spans several weeks.
3. What visa do I need to travel to China for lymphoma treatment?
Most patients use an S2 visa, designed for medical stays under 180 days, which requires an official hospital invitation letter, diagnostic records, proof of funds, and travel/medical insurance. Patients expecting a longer treatment or monitoring period may need an S1 visa instead. Apply as soon as you have your invitation letter and allow at least 4–6 weeks of processing buffer, since requirements vary by nationality.
Final Thoughts
China's top lymphoma centers — led by institutions like PUMCH, SYSUCC, Peking University Cancer Hospital, Ruijin Hospital, and dedicated cell-therapy networks like GoBroad — now offer internationally competitive CAR-T access at a fraction of US pricing, backed by real published clinical outcomes rather than marketing claims alone. The right hospital depends entirely on your specific lymphoma subtype, treatment history, and logistical needs.
If you're evaluating treatment options, the responsible next step is a remote case review with a qualified hematology-oncology team, supported by your existing pathology and treatment records. For guidance navigating hospital selection, eligibility screening, and logistics, see our https://www.chinacurelink.com/post/cancer-treatment-in-china-a-complete-guide-for-southeast-asian-patients-2026
About ChinaCureLink
ChinaCureLink helps patients across the world access the best cancer treatment at China's top hospitals, without the delays, language barriers, and administrative confusion that typically come with seeking care abroad.
We connect patients directly with China's top cancer hospitals, ensuring that from the first case submission through to treatment and follow-up, every step is guided, translated, and coordinated by a team experienced in cross-border patient care.
ChinaCureLink is proudly affiliated with Medebound HEALTH — founded by US physicians, with over 10 years of experience and more than 3,000 patients served worldwide, Medebound HEALTH is recognized by Forbes and it is one of the most trusted patient cross-border concierge service company across North America and the Asia Pacific.
Disclaimer
This article is for informational purposes only and is not medical or financial advice. Treatment eligibility, protocols, and costs vary by individual case — confirm specifics with a coordinator and treating physician before making any decisions.
References
PMC / National Library of Medicine — Recent advances in CAR T-cell therapy for lymphoma in China
ScienceDirect — Cost-Effectiveness Analysis of Relmacabtagene Autoleucel for Relapsed or Refractory Large B-Cell Lymphoma in China
Taylor & Francis — Cost-effectiveness of chimeric antigen receptor T-cell therapy for relapsed or refractory large B-cell lymphoma: a systematic review and meta-analysis
Comments